Climb Bio (CLYM) Baird Global Healthcare Conference 2025 summary

Company overview and strategy

• Focuses on developing monoclonal antibodies for high unmet need indications with clear regulatory paths and large commercial potential.

• Lead program, Budoprutug (Budo), targets CD19 for B-cell-mediated diseases; second asset, CLYM116, targets APRO for IgA nephropathy.

• Strategic indication selection is based on biological rationale, risk profiles, and commercial opportunities, grouped into three disease buckets: IgG4-mediated, single organ IgG1-3-mediated, and complex rheumatological diseases.

• Emphasizes a data-driven approach to expand into additional indications based on initial study results.

• Maintains a strong cash runway through 2027 to support multiple clinical milestones.

Lead asset (Budoprutug/Budo) development and differentiation

• Budo is a CD19-targeting monoclonal antibody designed to deplete pathogenic B-cells while preserving protective immunity.

• Offers both IV and subcutaneous formulations, with the latter showing high bioavailability, high concentration, and low viscosity in preclinical studies.

• Subcutaneous dosing provides flexibility for patient and physician preferences, supporting broader adoption in community settings.

• Differentiates from UPLINZA with higher CD19 affinity, unique Fc characteristics, and subcutaneous administration potential.

• Dosing regimen allows for infrequent administration, aiming for disease-free intervals and improved patient experience.

Clinical development progress and trial designs

• PMN (IgG4-mediated): Early data showed 60% complete renal response at 12 months and long-lived remissions after four doses; phase II study enrolling 45 patients in dose-escalation cohorts.

• ITP (single organ): Targeting patients unresponsive to prior therapies; phase I/II study with dose escalation and up to one year follow-up for platelet response.

• SLE (complex rheumatological): Early phase study with dose escalation in high CDI score patients, focusing on safety and efficacy as dose increases.

• Data from these studies will guide further expansion within each disease bucket.